Celldex Therapeutics, Inc. (CLDX) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Thu, Aug 6, 2026after close 37 8-K
Q1 FY2026Thu, May 7, 2026after close 37 8-K
Q4 FY2025Wed, Feb 25, 2026after close 56 8-K
Q3 FY2025Mon, Nov 10, 2025after close 41 8-K
Q2 FY2025Thu, Aug 7, 2025after close 38 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Thu, Feb 27, 2025after close 58 8-K

What they guided beta

Q3 FY2026 "Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027." exhibit
Q3 FY2026 "Topline data from this study are expected to be presented in late 2026." exhibit
Q3 FY2026 "Third Quarter 2026 Financial Highlights and 2026 Guidance Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2026 were $650.3 million compared to $717.6 million as of June 30, 2026." exhibit
Q3 FY2026 "Guidance: Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028." exhibit
Q2 FY2026 "EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Celldex Reports Second Quarter Financial Results and Provides Corporate Update Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027 Phase 3 barzolvolimab cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively enrolling; Phase 2 topline data in AD expected in late 2026 Positive results from Phase 1 trial of bispecific CDX-622 showed rapid, profound, dose-dependent reductions in serum tryptase and C" exhibit
Q2 FY2026 "Topline data from this study are expected to be presented in late 2026." exhibit
Q2 FY2026 "Second Quarter 2026 Financial Highlights and 2026 Guidance Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2026 were $717.6 million compared to $451.5 million as of March 31, 2026." exhibit
Q2 FY2026 "Guidance: Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CLDX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CLDX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

CLDX earnings date badge

HTML

<a href="https://veritasdata.dev/company/CLDX/"><img src="https://veritasdata.dev/embed/CLDX.svg" alt="CLDX earnings date" width="240" height="56"></a>

Markdown

[![CLDX earnings date](https://veritasdata.dev/embed/CLDX.svg)](https://veritasdata.dev/company/CLDX/)

Script

<script async src="https://veritasdata.dev/embed/CLDX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CLDX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.